Reduced high-density lipoprotein antioxidant function in patients with coronary artery disease and acute coronary syndrome.

ABSTRACT:

Results

Participants with CAD (n = 723) had 12% higher mean relative levels of nHDLox compared with those with invasively excluded CAD (n = 502, P < 0.001). Patients presenting with symptoms of an ACS had the highest nHDLox values when compared with the elective cohort (median 1.35, IQR 0.97 to 1.85, P < 0.001). In multivariate analysis adjusted for age, sex, body mass index, and hypertension, nHDLox was a strong independent predictor of ACS (P < 0.001) but not of CAD (P > 0.05).

Conclusion

HDL antioxidant function is reduced in patients with CAD. nHDLox is strongly associated with ACS.

Trial registration

German Clinical Trials Register DRKS00014037.

Funding

Brandenburg Medical School Theodor Fontane, the BIOX Stiftung, and NIH grants R01AG059501 and R03AG05946

SUBMITTER: Sasko B 

PROVIDER: S-EPMC11949010 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature